Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
$5.40
-$0.06(-1.81%)
At close: 4:00 PM EST
$5.40
-$0.06(-1.81%)
Day’s Range― - ―
52-Week Range$2.03 - $9.24
Previous CloseN/A
Volume59.09K
Average Volume (3M)150.61K
Market Cap
$278.11M
Enterprise Value$233.82M
Total Cash (Recent Filing)$92.37M
Total Debt (Recent Filing)$40.69M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 04, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding52,871,730
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.09
Price to Sales (P/S)2.28
P/FCF Ratio-8.03
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.07
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$9.35Price Target Upside73.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Addressable Market OpportunityManagement highlights a multi‑million patient population for the TearCare therapy in the U.S., indicating a sizable addressable market that could support sustained revenue expansion as adoption increases.
Standalone MIGS CommercializationA dedicated program to support standalone microinvasive glaucoma surgery aims to engage surgeons and build procedural demand, which could expand surgical revenue beyond combination cataract procedures.
Valuation Upside PotentialShares trade at a discount to similarly sized peers, presenting potential upside if execution accelerates and growth expectations lead to a re‑rating of the stock.
Bears Say
Competitive PressureLarger medical device and pharmaceutical firms introducing new glaucoma and dry eye therapies increase competitive pressure that could limit market share gains and constrain pricing power.
Guidance UncertaintyLack of formal guidance for the next fiscal year raises uncertainty around near‑term revenue and margin trajectories, making it harder for investors to model future performance.
Reimbursement And Fee RiskPotential reductions in reimbursement or surgeon fee cuts pose a risk to procedure economics and could reduce revenue per case and overall pricing flexibility.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.03 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $278.11M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Mar 04, 2026 which is in 9 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.093.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.15.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 52,871,730 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went up 16.4%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.35 (73.15% Upside)
$9.35 (73.15% Upside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $782.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
-57.91%
Trailing 12-Months
Asset Growth
-18.53%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
SGHT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with several positive developments such as increased revenue guidance, successful payer coverage for TearCare, and growth in Surgical Glaucoma revenue. However, these are balanced by challenges including a decline in overall revenue and Dry Eye segment revenue, impact of tariff costs, and the reported net loss.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$9.35
▲(73.15% Upside)
Technical Analysis
Ownership Overview
35.04% Insiders
5.62% Mutual Funds
13.61% Other Institutional Investors
38.70% Public Companies and
Individual Investors